MA53872A - Variants du facteur de croissance de fibroblastes modifiés en tant qu'antagonistes du récepteur - Google Patents

Variants du facteur de croissance de fibroblastes modifiés en tant qu'antagonistes du récepteur

Info

Publication number
MA53872A
MA53872A MA053872A MA53872A MA53872A MA 53872 A MA53872 A MA 53872A MA 053872 A MA053872 A MA 053872A MA 53872 A MA53872 A MA 53872A MA 53872 A MA53872 A MA 53872A
Authority
MA
Morocco
Prior art keywords
growth factor
receptor antagonists
modified fibroblasts
factor variants
variants
Prior art date
Application number
MA053872A
Other languages
English (en)
Inventor
Jennifer Cochran
Sung Jin Park
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MA53872A publication Critical patent/MA53872A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MA053872A 2018-10-09 2019-10-09 Variants du facteur de croissance de fibroblastes modifiés en tant qu'antagonistes du récepteur MA53872A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862743414P 2018-10-09 2018-10-09

Publications (1)

Publication Number Publication Date
MA53872A true MA53872A (fr) 2021-08-18

Family

ID=70163877

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053872A MA53872A (fr) 2018-10-09 2019-10-09 Variants du facteur de croissance de fibroblastes modifiés en tant qu'antagonistes du récepteur

Country Status (9)

Country Link
US (1) US20220249611A1 (fr)
EP (1) EP3863660A4 (fr)
JP (1) JP2022513178A (fr)
KR (1) KR20210091147A (fr)
CN (1) CN113194980A (fr)
AU (1) AU2019359295A1 (fr)
CA (1) CA3115772A1 (fr)
MA (1) MA53872A (fr)
WO (1) WO2020076987A2 (fr)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030036506A1 (en) * 2000-12-08 2003-02-20 Kranz David M. Mutated class I major histocompatibility proteins and complexes
US7790682B1 (en) * 2003-12-02 2010-09-07 The Florida State University Research Foundation, Inc. Engineered human acidic fibroblast growth factors and associated methods
EP1881067A1 (fr) * 2006-07-18 2008-01-23 Direvo Biotech AG Mannanases
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
NZ580530A (en) * 2007-06-06 2012-04-27 Domantis Ltd Anti vegf polypeptides, antibody variable domains and antagonists
US20160039896A1 (en) * 2009-01-18 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Polypeptides targeting vascular endothelial growth factor receptor-2 and alpha v beta 3 integrin
US9023644B2 (en) * 2011-12-16 2015-05-05 Wisconsin Alumni Research Foundation FGF having enhanced stability
PL221356B1 (pl) * 2012-04-21 2016-03-31 Wrocławskie Ct Badań Eit & Spółka Z Ograniczoną Odpowiedzialności Zmodyfikowany genetycznie, rekombinowany czynnik wzrostu fibroblastów (FGF1) skoniugowany z nanocząsteczkami metalu lub tlenku metalu, jego sekwencja DNA i aminokwasowa oraz zastosowanie
US9290557B2 (en) * 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
WO2017075260A1 (fr) * 2015-10-30 2017-05-04 Salk Institute For Biological Studies Traitement de l'hyperglycémie induite par des stéroïdes avec des analogues de facteur de croissance des fibroblastes (fgf) 1
WO2018018010A1 (fr) * 2016-07-21 2018-01-25 Metacrine, Inc. Mutants de fgf et leurs utilisations

Also Published As

Publication number Publication date
EP3863660A2 (fr) 2021-08-18
WO2020076987A3 (fr) 2020-06-04
WO2020076987A2 (fr) 2020-04-16
KR20210091147A (ko) 2021-07-21
AU2019359295A1 (en) 2021-06-03
US20220249611A1 (en) 2022-08-11
CN113194980A (zh) 2021-07-30
EP3863660A4 (fr) 2022-07-06
CA3115772A1 (fr) 2020-04-16
JP2022513178A (ja) 2022-02-07

Similar Documents

Publication Publication Date Title
MA51232A (fr) Indane-amines utiles en tant qu'antagonistes de pd-l1
EP3773563C0 (fr) Promédicaments d'antagonistes de c5ar bicycliques fusionnés
LT3762380T (lt) Fenilpirolidinono formilpeptido 2 receptoriaus antagonistai
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
EP3814824A4 (fr) Prédiction de paramètres d'éclairage structuré
MA53835A (fr) Lactams bicycliques en tant qu'inhibiteurs de la protéine kinase 1 interagissant avec des récepteurs pour le traitment p.e. de maladies inflammatoires
EP3600434A4 (fr) Traitement de l'hypertension pulmonaire
MA52249A (fr) Antagonistes de l'intégrine humaine (alpha4) (beta7)
MA53110A (fr) Composés polycycliques en tant qu'inhibiteurs de la tyrosine-kinase de bruton
EP3860977A4 (fr) Antagonistes de l'intégrine
EP3481814A4 (fr) Antagonistes de l'intégrine tetrahydronaphthyridinepentanamide
MA47736A (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1
EP3492471A4 (fr) Composé bicyclique fusionné pour inhiber l'activité de la tyrosine kinase
MA51337A (fr) Inhibiteurs spiro exo-aza de l'interaction ménine-mll
EP3953331A4 (fr) Pyrazolesulfonamides en tant qu'agents antitumoraux
EP3950060A4 (fr) Composition favorisant la sécrétion de vésicules extracellulaires
EP3603660A4 (fr) Nouvelle application pour facteur de croissance des fibroblastes humains mutants à action prolongée
EP3496662A4 (fr) Protéine dérivée de la soie pour le traitement d'une inflammation
EP3632898A4 (fr) Antagoniste d'ep4
MA53643A (fr) Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6
EP3703680A4 (fr) Antagonistes du récepteur muscarinique m4 à l'acétylcholine
IT201700100643A1 (it) Struttura di casseratura per l'esecuzione di getti per la realizzazione di solai
EP3697781C0 (fr) Antagonistes du récepteur muscarinique de l'acétylcholine m4
EP3697428A4 (fr) Peptides sécréteurs artificiels pour la production de protéines hétérologues
EP3844166A4 (fr) Macrocycles substitués utiles en tant qu'inhibiteurs de kinase